반응식
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[CH:19]=[CH:18][CH:17]=[CH:16][C:15]=2[O:20][CH2:21][CH2:22][N:23]2[CH2:28][CH2:27]OC[CH2:24]2)[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:29](OC(N1CCN(C2C=CC=CC=2O)CC1)=O)(C)(C)C.CN1CCCC(O)C1>>[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][N:11]([C:14]2[CH:19]=[CH:18][CH:17]=[CH:16][C:15]=2[O:20][CH:21]2[CH2:29][CH2:27][CH2:28][N:23]([CH3:24])[CH2:22]2)[CH2:10][CH2:9]1)=[O:7])([CH3:2])([CH3:3])[CH3:4]참가 물질
4
반응물 3
생성물 1
실험 절차
The title compound was prepared in a manner similar to 4-[2(2-Morpholin-4-yl-ethoxy)-phenyl]-piperazine-1-carboxylicacid tert-butyl ester except that 4-(2-hydroxy-phenyl)-piperazine-1-carboxylic acid tert-butyl ester was coupled to 1-methyl-piperidin-3-ol.
출처 및 근거
- ORD 기록
- ord-018fbdc1147f474b85b3273ed44ec37e
- 출처 데이터셋
- uspto-grants-2007_03
- 특허 번호
- US07186715B2
연결된 노트
불러오는 중…